立体定向消融放疗治疗I期小细胞肺癌的多中心经验
该多中心队列研究评估了立体定向消融放疗(SABR)在不可手术I期(T1-T2N0)小细胞肺癌(SCLC)中的疗效与安全性,共纳入74例患者、76个病灶。中位随访18个月,1年和3年局部控制率分别为97.4%和96.1%。接受化疗者无病生存和总生存均显著改善,≥2级放射性肺炎发生率为5.2%。
要点
- SABR(≥50 Gy)联合化疗应被视为T1-T2N0 SCLC的标准选择。
- 接受化疗者中位无病生存(61.3 vs 9.0个月)和总生存(31.4 vs 14.3个月)更优。
- ≥2级放射性肺炎发生率5.2%,治疗失败以远处转移最常见(占复发的45.8%)。
核心结论
- 对于不可手术的T1-T2N0小细胞肺癌,SABR(≥50 Gy)联合化疗应被视为标准治疗选择。
研究设计与样本
- 多中心队列研究,纳入24家机构经组织学确诊的T1-T2N0M0 SCLC患者74例,共治疗76个病灶。
- 中位随访18个月,采用Kaplan-Meier法评估生存,单因素和多因素分析确定预后预测因素。
主要发现
- 1年和3年局部控制率分别为97.4%和96.1%;中位无病生存期49.7个月,1年和3年无病生存率分别为58.3%和53.2%。
- 中位疾病特异性生存52.3个月,1年和3年分别为84.5%和64.4%;中位总生存17.8个月,1年和3年分别为69.9%和34.0%。
- 接受化疗者中位无病生存(61.3 vs 9.0个月,P=.02)和中位总生存(31.4 vs 14.3个月,P=.02)均显著优于未接受化疗者。
- 多因素分析显示接受化疗是DFS和OS更优的独立预测因素(P=.01)。
- ≥2级放射性肺炎发生率为5.2%;治疗失败最常见为远处转移(占复发的45.8%),其次为淋巴结(25.0%)和「其他肺叶」(20.8%),中位出现时间5至7个月。
关键数值与推荐
- 中位SABR剂量和分次为50 Gy分5次。
- 56%的病例接受了化疗,23%接受了预防性颅脑照射。
- 中位年龄72岁,中位肿瘤大小2.5 cm。
临床怎么用
- 对于不可手术的T1-T2N0 SCLC患者,可考虑SABR(≥50 Gy)联合化疗作为标准治疗选项。
- 治疗前应评估患者是否适合接受化疗,因化疗与显著改善的无病生存和总生存相关。
- 治疗后需关注远处转移和淋巴结失败,中位出现时间约5至7个月。
局限性
- 本文未报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For inoperable stage I (T1-T2N0) small cell lung cancer (SCLC), national guidelines recommend chemotherapy with or without conventionally fractionated radiation therapy. The present multi-institutional cohort study investigated the role of stereotactic ablative radiation therapy (SABR) for this population. METHODS AND MATERIALS: The clinical and treatment characteristics, toxicities, outcomes, and patterns of failure were assessed in patients with histologically confirmed stage T1-T2N0M0 SCLC. Kaplan-Meier analysis was used to evaluate the survival outcomes. Univariate and multivariate analyses identified predictors of outcomes. RESULTS: From 24 institutions, 76 lesions were treated in 74 patients (median follow-up 18 months). The median age and tumor size was 72 years and 2.5 cm, respectively. Chemotherapy and prophylactic cranial irradiation were delivered in 56% and 23% of cases, respectively. The median SABR dose and fractionation was 50 Gy and 5 fractions. The 1- and 3-year local control rate was 97.4% and 96.1%, respectively. The median disease-free survival (DFS) duration was 49.7 months. The DFS rate was 58.3% and 53.2% at 1 and 3 years, respectively. The median, 1-year, and 3-year disease-specific survival was 52.3 months, 84.5%, and 64.4%, respectively. The median, 1-year, and 3-year overall survival (OS) was 17.8 months, 69.9%, and 34.0% respectively. Patients receiving chemotherapy experienced an increased median DFS (61.3 vs 9.0 months; P=.02) and OS (31.4 vs 14.3 months; P=.02). The receipt of chemotherapy independently predicted better outcomes for DFS/OS on multivariate analysis (P=.01). Toxicities were uncommon; 5.2% experienced grade ≥2 pneumonitis. Post-treatment failure was most commonly distant (45.8% of recurrence), followed by nodal (25.0%) and "elsewhere lung" (20.8%). The median time to each was 5 to 7 months. CONCLUSIONS: From the findings of the largest report of SABR for stage T1-T2N0 SCLC to date, SABR (≥50 Gy) with chemotherapy should be considered a standard option.
引用
- Verma V, Simone CB, Allen PK, et al. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28011047. doi:10.1016/j.ijrobp.2016.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。